Literature DB >> 8445509

Disposition of liposomal gentamicin following intrabronchial administration in rabbits.

P Demaeyer1, E M Akodad, E Gravet, P Schietecat, J P Van Vooren, A Drowart, J C Yernault, F J Legros.   

Abstract

Use of liposomes as carriers of gentamicin for intrabronchial pulmonary delivery was investigated in rabbits. Gentamicin, in isotonic glutamic acid buffer, pH 4.5, was encapsulated in multilamellar vesicles (MLVs) and administered intrabronchially. Higher drug concentrations were found at the pulmonary site of liposome instillation for 1 day as compared with free unencapsulated antibiotic. When time-course distributions of gentamicin given in the liposomal or free form were measured in bronchoalveolar lavages (BAL), similar accumulations were observed up to 4 h, but the drug remained longer (24 h) after administration of the liposomal formulation. Higher amounts of antibiotic were detected in BAL supernatant 1 h after instillation of plain gentamicin; this difference stopped being significant after 4 h. A microbiological assay outlined the bacteriostatic activity of gentamicin released from MLVs and recovered in BAL supernatant. Liposomal gentamicin accumulated in the BAL cell pellet 1 h after intrabronchial instillation; it decreased progressively but minute amounts were still detected after 1 day. On the contrary, no gentamicin was found in the pellet at any time after free drug administration. Comparison of aminoglycoside concentrations in plasma and kidneys indicated lower and constant levels when the liposomal form was instilled. Liposome encapsulation altered the disposition of gentamicin in a way suggesting improved pulmonary concentration and lower systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445509     DOI: 10.3109/02652049309015314

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  6 in total

1.  Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.

Authors:  A van't Veen; J W Mouton; D Gommers; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.

Authors:  Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

4.  Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.

Authors:  Jean-Francois Marier; Jean Lavigne; Murray P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 6.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.